Pricing Log in Create free account

ADC Therapeutics SA (ADCT) vs Zentalis Pharmaceuticals, Inc. (ZNTL)

ADC Therapeutics SA and Zentalis Pharmaceuticals, Inc. are both Biotechnology companies. Zentalis Pharmaceuticals, Inc. is the larger, with a market value of $212.1M against $190.2M — 1.1× the size. Zentalis Pharmaceuticals, Inc. has the higher net margin (0.00% vs −121.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, ADC Therapeutics SA leads on 8 and Zentalis Pharmaceuticals, Inc. on 4.

Valuation

Metric ADCT ZNTL Biotechnology median
P/E n/m n/m 8.42
P/S 2.90 n/m 10.01
P/B n/m 1.12 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m 0.09 0.61
EV/Sales 1.61 n/m 9.41
Earnings yield (44.30%) (86.67%) (31.85%)
Free cash flow yield (44.04%) (79.76%) (24.58%)

Profitability

Metric ADCT ZNTL Biotechnology median
Gross margin 88.86% 0.00% 65.16%
Operating margin (125.08%) 0.00% 0.00%
Net margin (121.77%) 0.00% 0.00%
Free cash flow margin (127.72%) 0.00% 0.00%
Return on equity 45.35% (66.75%) (56.36%)
Return on assets (32.25%) (49.22%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADCT ZNTL Biotechnology median
Revenue growth (TTM) 3.03% — 6.02%
EPS growth (last fiscal year) 30.86% 18.03% 30.26%
Revenue growth, 5-year CAGR 103.35% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADCT ZNTL Biotechnology median
Debt to equity (0.51) 0.00 0.00
Current ratio 3.03 4.82 4.72
Net debt to EBITDA 1.22 1.59 0.96

Dividend

Metric ADCT ZNTL Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric ADCT ZNTL Biotechnology median
Market cap 190.23m 212.07m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack